Marein prevented LPS-induced osteoclastogenesis by regulating the NF-κB pathway in vitro

Abstract

Gram-negative bacterial infection causes many bone diseases such as osteolysis, osteomyelitis and septic arthritis. Lipopolysaccharide (LPS), a bacteria product, played an important role in this process. Drugs that inhibited LPS-induced osteoclastogenesis were urgently needed for the prevention of bone destruction in infective bone diseases. Marein, a major bioactive compound of Coreopsis.tinctoria, which possesses anti-oxidative, anti-inflammatory, anti-hypertensive, anti-hyperlipidemic and anti-diabetic effects. In this study, the effect of marein on RAW264.7 cells was measured by CCK-8 assay; TRAP staining was used to determine osteoclastogenesis; the levels of osteoclast-related genes and NF-κB-related proteins were analyzed by WB; the levels of pro-inflammatory cytokines were quantified by ELISA. Our results showed that marein inhibited LPS-induced osteoclast formation from osteoclast precursor RAW264.7 cells. The effect of marein was related to its inhibitory function on expressions of pro-inflammatory cytokines and osteoclast-related genes including RANK, TRAF6, MMP-9, CK and CAⅡ. Besides, marein treatment could inhibit LPS-induced activation of NF-κB signaling pathway in RAW264.7 cells. Meanwhile, inhibition of NF-κB signaling pathway decreased the formation of osteoclasts and expression of pro-inflammatory cytokines which were LPS-induced. Collectively, marein could prevent LPS-induced osteoclast formation in vitro by regulating NF-κB signaling pathway. These findings provided evidence that marein might be beneficial as a valuable choice for the prevention and treatment of bacteria-induced bone destruction disease, and gave new insights for understanding its possible mechanism.

The marine factor 3,5-dihydroxy-4-methoxybenzyl alcohol expresses the anti-inflammatory effects in mouse macrophages RAW264.7 cells in vitro

“…Next, we investigated the suppressive effects of DHMBA on in ammatory macrophage RAW264.7 cells with LPS treatment. LPS is well known to enhance the in ammatory activity of mouse macrophage RAW264.7 cells [5,9]. It was determined whether DHMBA attenuates the repressive effects on the proliferation or the stimulatory effects on the death of RAW264.7 cells cultured in the presence of LPS in vitro (Fig.…”

“…DHMBA inhibits osteoclastogenesis of RAW264.7 cells RAW264.7 cells are well used as modeled cells in osteoclastogenesis studies [4,8]. Osteoclasts are differentiated from the monocyte-macrophage lineage [9]. LPS has been shown to stimulate osteoclastogenesis of RAW264.7 cells by activating the NF-κB pathway [9].…”

“…Osteoclasts are differentiated from the monocyte-macrophage lineage [9]. LPS has been shown to stimulate osteoclastogenesis of RAW264.7 cells by activating the NF-κB pathway [9]. We investigated whether DHMBA in uences osteoclastogenesis of RAW264.7 cells cultured with LPS.…”

“…RAW264.7 cells are progressively used as modeled macrophages in in ammatory conditions in vitro, This cell line is also accepted as a modeled cell of osteoclastogenesis study [4,8]. Osteoclasts are differentiated from the monocyte-macrophage lineage [9]. Lipopolysaccharide (LPS) is a core antigen of gram-negative bacteria, which activates the innate immune system of the host [10].…”

“…LPS is an endotoxin that provides a persistent in ammatory stimulus to the tissue [11]. LPS induces osteoclastogenesis of RAW264.7 cells by regulating NF-κB-related signaling pathways and transcriptional activity [9].…”